Le Lézard

U.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ...

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has approved INQOVI (decitabine and cedazuridine) plus venetoclax as a ...

'I'm terminally ill, I'm entitled to a respectful and peaceful death, but that's not happening'

Colin Porter has cancer and wants to live out what time he has left with dignity, but claims events are conspiring against ...
Le Lézard

National Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

The National Kidney Foundation (NKF) announced today that its Innovation Fund has invested in Biohope, a biotechnology company developing precision diagnostics designed to personalize ...

Active Biotech AB: European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration ...

Lund, Sweden - May 13, 2026 Active Biotech (NASDAQ Stockholm: ACTI) today announced positive feedback from the European regulatory authorities and ethics committee regarding the clinical proof-of-conc ...
Oncology Nursing News

FDA Approves Oral Decitabine/Cedazuridine and Venetoclax for AML

On May 13, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi) tablets in combination with ...